Zura Bio Ltd 8-K/A

What Happened
Zura Bio Ltd (ZURA) filed an Item 9.01 Form 8‑K on February 26, 2026 to furnish exhibits related to a securities offering. The filing references an Underwriting Agreement dated February 24, 2026 among Zura Bio and the underwriters Leerink Partners LLC, Piper Sandler & Co., and Cantor Fitzgerald & Co., plus a form of pre‑funded warrant, legal opinion and consent from Ogier (Cayman) LLP, and two press releases dated February 24 and 25, 2026.

Key Details

• Filing date: February 26, 2026 (Form 8‑K, Item 9.01 — Financial Statements and Exhibits).
• Underwriting Agreement dated February 24, 2026 with underwriters: Leerink Partners LLC, Piper Sandler & Co., and Cantor Fitzgerald & Co.
• Exhibits include: form of pre‑funded warrant, Ogier (Cayman) LLP legal opinion and consent, and launch & price press releases (Feb 24 and Feb 25, 2026).
• Cover Page Interactive Data File (Inline XBRL) is included with the filing.

Why It Matters
The exhibits indicate Zura Bio undertook a securities offering involving underwriters and pre‑funded warrants. That activity can affect the company’s capital position and potentially dilute existing shareholders depending on offering size and instrument terms. Investors should review the referenced underwriting agreement and the Feb 24/25 press releases (filed as exhibits) for details on offering size, price, proceeds and any expected use of funds to assess impact.